Fighting Breast and Ovarian Cancer With a Lupus Antibody
After discovering a specific lupus antibody that can penetrate cancer cells and, with a grant from Women's Health Research at Yale, showing it makes cancer cells vulnerable to standard treatments, Dr. Peter Glazer and his colleagues are moving a treatment to clinical trials.
Yale Physicians Share the Symptoms of Ovarian Cancer
September is ovarian cancer awareness month and while ovarian cancer is rare, the survival rate is low. Ovarian cancer is not easily detectable in its early stages. According to the American Cancer Society, the most common symptoms include bloating, pelvic-abdominal pain, and urinary symptoms. News 8 spoke with co-directors of the Sexual Intimacy and Menopause Program at Smilow Cancer Hospital in New Haven.Source: WTNH
Using Particles That Are Smaller Than the Head of a Pin to Treat Cancer
Thanks in part to research begun more than a decade ago with funding from Women’s Health Research at Yale, Dr. W. Mark Saltzman is working with colleagues on a way to deploy effective cancer-fighting medication safely with the help of nanoparticles.
Treatment with Genetically Altered Viruses Targets and Destroys Ovarian Cancer in Mice
Researchers have successfully eliminated chemotherapy-resistant ovarian cancer cells in mice using a single injection of two viruses genetically combined and altered to be safe, leading to long-term survival and demonstrating a potential breakthrough treatment for women.
Carocari Gift to Support Dr. Schwartz’s Ovarian Cancer Research
Deborah Carocari was only 36 when she was diagnosed with a rare form of advanced but low-grade ovarian cancer. At that time she received a prognosis of several months to a year from her physician, Peter Schwartz, MD, now the John Slade Ely Professor of Obstetrics, Gynecology, and Reproductive Sciences and Vice Chair, Gynecology. Debbie went on to defy those odds and battle the cancer for the next two decades. Although she ultimately succumbed to the disease, a generous gift from her estate is now making possible further ovarian cancer research by Dr. Schwartz.
Greenwich woman helps lead early detection battle against ovarian, breast cancers
GREENWICH — Greenwich Hospital will spearhead an effort to help doctors better recognize the symptoms and signs of ovarian cancer and breast cancer and more effectively diagnose the potentially deadly diseases.Source: Greenwich Time
Yale Cancer Center researchers find genetic explanations behind the rapid spread of ovarian cancer
In a breakthrough study, Yale Cancer Center (YCC) researchers have defined the genetic characteristics of primary, metastatic and recurrent ovarian tumors and evaluated new targeted therapies to treat the disease. The findings are reported today in the Proceedings of the National Academy of Science (PNAS) online early edition.
Knowing the Risks: The Genetics of Breast and Ovarian Cancer
Dr. Ryan Jensen’s work, spurred by a pair of WHRY grants, continues progress toward models uncovering how genetic mutations lead to cancer and helping guide patients and doctors toward decisions that can produce the best health outcomes.
Women’s Health Research at Yale: 2012 Pilot Studies Awarded
Gender-Specific Mechanisms for Understanding Smoking Addiction, Enhancing Treatments for Breast and Ovarian Cancer, the Value of Breast Ultrasound Screening, and Cellular Mechanisms Underlying Gender Differences in Neurodegenerative Diseases
Why the Latest Screening Tests and Treatments Offer Hope for Ovarian Cancer
Ovarian cancer is the second most common gynecologic cancer in the United States. It also accounts for more deaths than any other cancer of the female reproductive system, according to the Centers for Disease Control and Prevention (CDC).Source: Everyday Health
HEALTH NOTES: Black and Hispanic Cancer Patients Are Underrepresented in Clinical Trials
A new study has shown that clinical trials for new cancer medications rarely analyze data on safety and effectiveness by race and that black and Hispanic patients are consistently underrepresented among participants.